The Detection of CMV Pp65 and IE1 in Glioblastoma Multiforme
Overview
Affiliations
Glioblastoma multiforme (GBM) is a highly lethal brain tumor affecting children and adults, with the majority of affected individuals dying from their disease by 2 years following diagnosis. Other groups have reported the association of cytomegalovirus (CMV) with GBM, and we sought to confirm these findings in a large series of patients with primary GBM from our institution. Immunohistochemical analysis of paraffin embedded tissue sections was performed on 49 newly diagnosed GBM tumors, the largest series reported to date. We confirmed the presence of CMV pp65 on 25/49 (51%) and of IE1 on 8/49 (16%) of these tumors. While pp65 and IE1 are generally found in the nucleus of cells that are permissibly infected by CMV, GBM in this series had mostly cytoplasmic staining, with only 16% having nuclear staining for one or both of these antigens. We infected GBM cell lines with a laboratory strain of CMV, and found that most of the staining was cytoplasmic, with some perinuclear localization of IE1. To test the potential for CMV infected GBM cells to be recognized by CMV pp65 and IE1 specific cytotoxic T lymphocytes (CTL), we used CMV infected GBM cell lines in cytotoxicity assays with human leukocyte antigen partially matched CMV CTL. Lysis of CMV infected GBM tumor cells was accentuated by pre-treating these cell lines with either the demethylating agent decitabine or interferon-γ, both of which were shown to increase MHC Class I and II expression on tumor cells in vitro. These studies confirm the presence of CMV pp65 or IE1 on approximately half of GBM, with the possibility that CMV positive tumor cells can be recognized by CMV pp65/IE1 specific T cells.
Viruses in glioblastoma: an update on evidence and clinical trials.
Gunasegaran B, Ashley C, Marsh-Wakefield F, Guillemin G, Heng B BJC Rep. 2024; 2(1):33.
PMID: 39516641 PMC: 11524015. DOI: 10.1038/s44276-024-00051-z.
Glioblastoma Vaccines as Promising Immune-Therapeutics: Challenges and Current Status.
Squalli Houssaini A, Lamrabet S, Nshizirungu J, Senhaji N, Sekal M, Karkouri M Vaccines (Basel). 2024; 12(6).
PMID: 38932383 PMC: 11209492. DOI: 10.3390/vaccines12060655.
Tumor Antigens beyond the Human Exome.
Emilius L, Bremm F, Binder A, Schaft N, Dorrie J Int J Mol Sci. 2024; 25(9).
PMID: 38731892 PMC: 11083240. DOI: 10.3390/ijms25094673.
RNA aggregates harness the danger response for potent cancer immunotherapy.
Mendez-Gomez H, DeVries A, Castillo P, von Roemeling C, Qdaisat S, Stover B Cell. 2024; 187(10):2521-2535.e21.
PMID: 38697107 PMC: 11767857. DOI: 10.1016/j.cell.2024.04.003.
Muller L, Di Benedetto S Int J Mol Sci. 2024; 25(2).
PMID: 38255826 PMC: 10815036. DOI: 10.3390/ijms25020753.